Patent dance ruling moves biosimilars industry forward, Sandoz says

The US Supreme Court has given a potential boost to the biosimilars industry with its ruling in a high-profile case involving the US biotech major Amgen (Nasdaq: AMGN) and Sandoz, the generics division of the Swiss pharma giant Novartis (NOVN: VX).

In a unanimous decision on Monday, the court ruled against Amgen’s argument that biosimilar manufacturers should be forced to delay their 180-day marketing notices until after the US Food and Drug Administration (FDA) had approved their marketing applications.

"As the global leader in biosimilars, it is our responsibility to help eliminate barriers so patients can access more affordable medicine"